1. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.
- Author
-
Spiegel, Jonathan, Pirraglia, Elizabeth, Osorio, Ricardo S., Glodzik, Lidia, Li, Yi, Tsui, Wai, Saint Louis, Leslie A., Randall, Catherine, Butler, Tracy, Jinfeng Xu, Zinkowski, Raymond P., Zetterberg, Henrik, Fortea, Juan, Fossati, Silvia, Wisniewski, Thomas, Davies, Peter, Blennow, Kaj, de Leon, Mony J., and Xu, Jinfeng
- Subjects
- *
ALZHEIMER'S disease , *TAU proteins , *CEREBROSPINAL fluid , *PHOSPHORYLATION , *BIOMARKERS , *MEDICAL research , *ALZHEIMER'S disease diagnosis , *NERVE tissue proteins , *PEPTIDES , *RESEARCH funding , *LOGISTIC regression analysis , *CROSS-sectional method , *CASE-control method , *RECEIVER operating characteristic curves - Abstract
Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD). While both are pathologically validated, their relative diagnostic performances are not well known. This cross-sectional diagnostic study of 87 normal (NL) subjects and 28 AD subjects compared CSF P-tau231 with CSF P-tau181. Logistic regression modeling demonstrated that the P-tau231 was superior to the P-tau181 in the diagnostic classifications. At a fixed 85% sensitivity cutoff, the ROC analysis shows that P-tau231 has greater overall specificity than P-tau181. While both P-tau analytes demonstrated equivalent negative predictive accuracies, P-tau231 yielded significantly fewer false positives. Moreover, P-tau231, but not P-tau181, demonstrated sensitivity to the E4 genotype. A postmortem validation with 9 AD subjects confirmed the superiority of the CSF P-tau231 specificity. This study suggests that P-tau231 has the potential to improve the CSF tau biomarker diagnosis of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF